Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug therapy for hepatitis B.

A Regev1, E R Schiff

  • 1Division of Hepatology, Center for Liver Diseases, University of Miami School of Medicine, Miami, Fla., USA.

Advances in Internal Medicine
|January 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A self-adaptive hardware with resistive switching synapses for experience-based neurocomputing.

Nature communications·2023
Same author

SM-Omics is an automated platform for high-throughput spatial multi-omics.

Nature communications·2022
Same author

Application of ventricular tachyarrhythmia definitions of the updated Lambeth Conventions provides incompatibility with earlier results, masks antifibrillatory activity and reduces inter-observer agreement.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2019
Same author

Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease.

Human genetics·2018
Same author

Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib.

Clinical pharmacology and therapeutics·2015
Same author

Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection.

Journal of viral hepatitis·2015
Same journal

Nutrition and nutritional diseases in the Orient.

Advances in internal medicine·2010
Same journal

Nutritional requirements in disease.

Advances in internal medicine·2010
Same journal

Problem of the rhesus antigen in medicine.

Advances in internal medicine·2010
Same journal

Penicillin treatment of subacute bacterial endocarditis.

Advances in internal medicine·2010
Same journal

Physiologic and medical aspects of aviation and deep sea diving.

Advances in internal medicine·2010
Same journal

Progress in the development of insecticides for prevention of insect-borne diseases.

Advances in internal medicine·2010
See all related articles

New therapies for chronic hepatitis B virus (HBV) infection are emerging, moving beyond interferon (IFN). Combination therapies with nucleoside analogues and immune modulators show promise for improved efficacy and resistance prevention.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Interferon (IFN) was the primary treatment for chronic hepatitis B virus (HBV) infection.
  • Recent advancements in understanding HBV replication and nucleoside analogue development have transformed treatment options.

Purpose of the Study:

  • To review emerging therapeutic strategies for chronic HBV infection.
  • To discuss the potential of combination therapies in managing HBV.

Main Methods:

  • Review of recent literature on HBV therapeutics.
  • Analysis of nucleoside analogues and immune-modulating agents.
  • Exploration of therapeutic vaccination and gene therapy.

Main Results:

  • Lamivudine offers an alternative to IFN with similar efficacy and fewer side effects.

Related Experiment Videos

  • Combination therapy, particularly with nucleoside analogues and immune modulators, is a promising strategy.
  • Therapeutic vaccination and gene therapy are under investigation.

    • Conclusions:

    • The future of HBV treatment likely involves combination therapy.
    • Combining nucleoside analogues with immune modulators like IFN or therapeutic vaccines may offer synergistic effects.
    • Combination approaches could delay or prevent the emergence of drug-resistant HBV mutants.